Personal Capital Advisors Corp Reduces Position in Merck & Company, Inc. (MRK)

Personal Capital Advisors Corp decreased its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 1.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 84,825 shares of the company’s stock after selling 1,329 shares during the quarter. Personal Capital Advisors Corp’s holdings in Merck & were worth $5,436,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Boston Partners raised its stake in Merck & by 2.6% during the first quarter. Boston Partners now owns 19,935,016 shares of the company’s stock valued at $1,266,671,000 after purchasing an additional 500,476 shares in the last quarter. Clearbridge Investments LLC raised its stake in Merck & by 0.6% during the first quarter. Clearbridge Investments LLC now owns 13,414,669 shares of the company’s stock valued at $852,368,000 after purchasing an additional 77,344 shares in the last quarter. Sanders Capital LLC raised its stake in Merck & by 3.3% during the first quarter. Sanders Capital LLC now owns 11,593,645 shares of the company’s stock valued at $752,482,000 after purchasing an additional 365,276 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Merck & by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 9,821,563 shares of the company’s stock valued at $624,064,000 after purchasing an additional 41,748 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in Merck & by 8.1% during the second quarter. Bank of Montreal Can now owns 9,723,813 shares of the company’s stock valued at $623,199,000 after purchasing an additional 732,720 shares in the last quarter. Hedge funds and other institutional investors own 73.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/17/personal-capital-advisors-corp-reduces-position-in-merck-company-inc-mrk.html.

A number of equities research analysts recently issued reports on the stock. Credit Suisse Group set a $72.00 price target on shares of Merck & and gave the company a “buy” rating in a research note on Tuesday, June 6th. BidaskClub downgraded shares of Merck & from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BMO Capital Markets reaffirmed a “buy” rating and set a $72.00 price target on shares of Merck & in a research note on Friday, September 8th. Cowen and Company reaffirmed a “hold” rating and set a $70.00 price target on shares of Merck & in a research note on Friday, September 1st. Finally, UBS AG upped their price target on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $70.00.

Merck & Company, Inc. (NYSE MRK) traded up 0.06% on Friday, reaching $66.16. 14,685,767 shares of the company traded hands. The stock has a 50 day moving average of $63.41 and a 200-day moving average of $63.72. Merck & Company, Inc. has a 1-year low of $58.29 and a 1-year high of $66.80. The stock has a market capitalization of $180.44 billion, a price-to-earnings ratio of 35.76 and a beta of 0.81.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.93 EPS. On average, equities analysts anticipate that Merck & Company, Inc. will post $3.87 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.84%. Merck &’s dividend payout ratio (DPR) is currently 76.11%.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply